This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
ADSTILADRIN
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
ESCAPE
FORT
NRG-GU 0101
Masofaniten (EPI-7386)
METANOVA
RTIRE
SHORTER
Right Side
PCCTC
DORA
IRONMAN
PROMISE
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SESAUA 2024
Southern CA GU Cancer Research Forum 2024
AUA Urology Advocacy Summit 2024
ASCO GU 2024
2024 UCSF-UCLA PSMA Conference
SUO 2023
All Conferences
View All
PCF
UroToday Home
Video Lectures
Keane's Corner
Keane's Corner VL
Search
Clear
Most recent
Most hits
Most likes
Most dislikes
Title alphabetical
Recently modified
Recently viewed
Author alphabetical
Random
10
20
30
40
50
The Changing Landscape in Advanced Bladder Cancer - Tom Keane
Details
(Length of Discussion: 16 min) Dr. Tom Keane discusses the rapidly changing landscape in advanced bladder cancer with the introduction of immune checkpoint inhibitors. To begin his discussion he references a presentation by Thomas Powles, MD from the 2018 ASCO GU meeting where Dr. Powles provided an overview of immune checkpoint inhibitors in urothelial carcinoma at the current time and Dr. Powles...
New Concepts in ADT- Thomas Keane
Details
(Length of Discussion: 21 min) Tom Keane brings new concepts in androgen deprivation therapy (ADT) to light specifically discussing agonists versus antagonists, new androgen receptor-targeted drugs, including immunotherapy biomarkers, and genomic testing. He reviews the current state of the CRPC treatment and ADT options for use in advanced metastatic disease and concludes with a discussion on tre...
Discussion of an Online Tool to Explore Evolving Practice Patterns in Renal Cell Carcinoma - Thomas Keane
Details
(Length of Discussion: 5 min) Dr. Thomas Keane discusses a group analysis of an online tool to explore evolving practice patterns among patients with renal cell carcinoma (RCC), a topic presented by Dr. Won Kim from UCSF. The complex and rapidly evolving treatment landscape for advanced RCC poses challenges for healthcare providers, particularly those in community settings, to make treatment decis...
Discussion of the IMmotion 151 Trial: Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma - Thomas Keane
Details
(Length of Discussion: 5 min) Dr. Thomas Keane reviews the IMmotion 151 Trial, a randomized Phase III Study of Atezolizumab Plus Bevacizumab versus Sunitinib in Untreated Metastatic Renal Cell Carcinoma. A topic presented by Robert J. Motzer, MD at the 2018 ASCO GU 2018 meeting. In this oral abstract session, Dr. Motzer presented the first phase III randomized clinical trial combining a PD-L1/PD-1...
Discussion of the CABOSUN trial - Advanced Renal Cell Carcinoma - Thomas Keane
Details
(Length of Discussion: 4 min) Dr. Thomas Keane reviews the Subgroup Analysis of Progression-free Survival and Objective Response Rate in the Alliance AO31203 CABOSUN trial for Advanced Renal Carcinoma presentation by Dr. Daniel George at the ASCO GU 2018 meeting. Cabozantinib, a small molecule designed to target the MET and ALK pathways in addition to VEGFR2 pathway has been shown to be superior t...
Discussion on FALCON: Impact of 18F-fluciclovine PET/CT on Clinical Management Choices for Men with Biochemically Recurrent Prostate Cancer
Details
(Length of Discussion: 4 min) Dr. Thomas Keane provides a commentary on the The FALCON Trial , the impact of 18F-fluciclovine PET/CT on clinical management choices for men with biochemically recurrent prostate cancer presented at the recent 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium . Eugene Jueren Teoh, MBBS, MRCP from the University of Oxford presented t...
Discussion on SPARTAN: A Study of Apalutamide in Men with Non-Metastatic Castration-resistant Prostate Cancer - Thomas Keane
Details
(Length of Discussion 17 min) Dr. Thomas Keane reviews recent groundbreaking data presented at the 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium focusing on the much awaiting results of the SPARTAN trial. Dr. Keane started by highlighting the SPARTAN Trial presentation by Dr. Eric Small. A Study of Apalutamide (ARN-509) in Men with Non-Metastatic Castration-r...
News Update: Apalutamide as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer - Thomas Keane
Details
(Length of Update: 4 min) As we start a new year, Dr. Thomas Keane provides an update on exciting news in the area of non-metastatic castration-resistant prostate cancer with the FDA granting priority review for apalutamide as a treatment for non-metastatic castration-resistant prostate cancer. Currently, there are no FDA-approved treatments for patients with non-metastatic CRPC. Watch Video from...
Start
Prev
1
2
Next
End
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free